MetaCap

Lipocine (LPCN) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lipocine (LPCN) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 53.2% versus a loss of 78.2%. Shuttle Pharmaceuticals is the larger company by market cap ($16.6 million vs $16.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LPCN-53.16%SHPH-78.19%
+273%+87%-100%
Nov 21, 20251 yearNov 20, 2026
LPCN-84.73%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LPCN versus SHPH key metrics
MetricLPCNSHPH
Share price$1.48$3.49
Market cap$16.39M$16.63M
1-day change-1.33%-10.51%
YTD return-81.57%-80.61%
1-year return-53.16%-78.19%
5-year return-92.30%—
EPS (TTM)$-1.32$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.98M—
Revenue growth (YoY)-82.35%—
Net income (latest FY)$-9.63M$-11.72M
Operating margin-524.69%—
Net margin-487.06%—
52-week high$12.37$44.40
52-week low$1.36$2.58
Distance from 52-week high-88.04%-92.14%
Analyst consensusnone—
Avg. price target upside+237.84%—
Average volume1.84M41.80K
Shares outstanding11.07M4.76M
Employees142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LPCN has outperformed SHPH by 25.0 percentage points over the past year.

About Lipocine

LPCN stock →

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

LPCN vs SHPH FAQ

Which is bigger, Lipocine or Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (SHPH) is larger, with a market capitalization of $16.63M compared with $16.39M for Lipocine (LPCN).

Which stock has performed better over the past year, LPCN or SHPH?

LPCN returned -53.16% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.

Are Lipocine and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons